丹化科技(600844.SH):2021年度預虧1.20億元
格隆匯1月28日丨丹化科技(600844.SH)公佈2021年年度業績預虧公吿,公司2021年度業績預計虧損1.20億元,扣除非經常性損益後歸屬於母公司股東淨利潤預計虧損1.22億元。
業績預虧的主要原因:
1、主營業務影響報吿期內公司化工產品的產銷情況基本正常,產品銷售均價比上年有所上升,經營性虧損有所減少。
2、計提減值準備公司對2021年末的存貨、長期待攤費用和長期股權投資計提資產減值損失3,209.14萬元,對應收賬款、其他應收款計提信用減值損失5,139.05萬元,兩項計提對歸屬於母公司的淨利潤的影響數為-6,730.24萬元,詳見公司同日披露的《關於計提減值準備的公吿》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.